quinoline-2-carboxylic acid D-valyl amide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: quinoline-2-carboxylic acid D-valyl amide
• 英文别名: (2R)-3-methyl-2-(quinoline-2-carbonylamino)butanoic acid
• 化学式: C₁₅H₁₆N₂O₃
• 分子量: 272.304
• InChiKey: QTALALPGMLVHRL-CYBMUJFWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  79.3
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  喹醛酰氯 、 D-缬氨酸 在 甲基叔丁基醚 、 sodium carbonate 作用下， 以 水 为溶剂， 反应 1.0h， 生成 quinoline-2-carboxylic acid D-valyl amide
  参考文献：
  名称：

  Practical, Stereoselective Synthesis of Palinavir, a Potent HIV Protease Inhibitor

  摘要：

  Palinavir is a potent peptidomimetic-based HIV protease inhibitor. We have developed a highly convergent and stereoselective synthesis which is amenable to the preparation of multikilogram quantities of this compound. The synthetic sequence proceeds in 24 distinct chemical steps (with several integrated, multistep operations) from commercially available starting materials. No chromatographies are required throughout the process, and the final product is purified by crystallization of its dihydrochloride salt to >99% homogeneity.

  DOI：

  10.1021/jo9702655

文献信息

• Selective Cysteine Protease Inhibitors and Uses Thereof
  申请人：Ahlfors Jan-Eric

  公开号：US20140038903A1

  公开（公告）日：2014-02-06

  The present invention relates to compounds of Formula I, II, IA-VA, IVA1-IVA5, IIIA1-IIIA5 and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more cysteine proteases. Also described are methods where the compounds of Formula I, II, IA-VA, IVA1-IVA5, IIIA1-IIIA5 are used in the prevention and/or treatment of various diseases and conditions in subjects, including cysteine protease-mediated diseases and/or caspase-mediated diseases such as sepsis, myocardial infarction, cancer, tissue atrophy, ischemia, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative diseases such as multiple sclerosis (MS), ALS, Alzheimer's disease, Parkinson's disease, and Huntington's disease).

  本发明涉及公式I、II、IA-VA、IVA1-IVA5、IIIA1-IIIA5化合物及其药物用途。本发明的特定方面涉及使用这些化合物选择性地抑制一个或多个半胱氨酸蛋白酶的用途。还描述了使用公式I、II、IA-VA、IVA1-IVA5、IIIA1-IIIA5化合物在预防和/或治疗受体中的各种疾病和病况，包括半胱氨酸蛋白酶介导的疾病和/或半胱氨酸蛋白酶介导的疾病，如败血症、心肌梗塞、癌症、组织萎缩、缺血、缺血性中风、脊髓损伤（SCI）、创伤性脑损伤（TBI）和神经退行性疾病，如多发性硬化症（MS）、ALS、阿尔茨海默病、帕金森病和亨廷顿病等。
• US9944674B2
  申请人：——

  公开号：US9944674B2

  公开（公告）日：2018-04-17
• Practical, Stereoselective Synthesis of Palinavir, a Potent HIV Protease Inhibitor
  作者：Pierre L. Beaulieu、Pierre Lavallée、Abraham、Paul C. Anderson、Colette Boucher、Yves Bousquet、Jean-Simon Duceppe、James Gillard、Vida Gorys、Chantal Grand-Maître、Louis Grenier、Yvan Guindon、Ingrid Guse、Louis Plamondon、François Soucy、Serge Valois、Dominik Wernic、Christiane Yoakim

  DOI：10.1021/jo9702655

  日期：1997.5.1

  Palinavir is a potent peptidomimetic-based HIV protease inhibitor. We have developed a highly convergent and stereoselective synthesis which is amenable to the preparation of multikilogram quantities of this compound. The synthetic sequence proceeds in 24 distinct chemical steps (with several integrated, multistep operations) from commercially available starting materials. No chromatographies are required throughout the process, and the final product is purified by crystallization of its dihydrochloride salt to >99% homogeneity.